Top Contract Development And Manufacturing Organization (CDMO) Outsourcing Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Contract Development And Manufacturing Organization (CDMO) Outsourcing Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Contract Development And Manufacturing Organization (CDMO) Outsourcing industry players.

Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Competitive Landscape

Global contract development and manufacturing organization (CDMO) outsourcing market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions.

Top Players in the CDMO Outsourcing Market

  • Lonza Group (Switzerland) 
  • Catalent (United States) 
  • WuXi Biologics (China) 
  • Samsung Biologics (South Korea) 
  • Siegfried Holding AG (Switzerland) 
  • Fujifilm Diosynth Biotechnologies (Japan) 
  • Recipharm AB (Sweden) 
  • Boehringer Ingelheim (Germany) 
  • MilliporeSigma (United States) 
  • Aenova Group (Germany) 
  • Fareva (France) 
  • Laurus Labs (India) 
  • Delpharm (France) 
  • Piramal Pharma Solutions (India) 
  • Almac Group (United Kingdom) 
  • Evonik Industries (Germany) 
  • Cambrex Corporation (United States) 
  • Lonza Group (Switzerland) 
  • Patheon (United States) 
  • WuXi AppTec (China) 

CDMO Outsourcing Market

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market size was valued at USD 228.63 billion in 2023 and is poised to grow from USD 243.26 billion in 2024 to USD 399.58 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032). 

Global contract development and manufacturing organization (CDMO) outsourcing market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Lonza Group (Switzerland) ', 'Catalent (United States) ', 'WuXi Biologics (China) ', 'Samsung Biologics (South Korea) ', 'Siegfried Holding AG (Switzerland) ', 'Fujifilm Diosynth Biotechnologies (Japan) ', 'Recipharm AB (Sweden) ', 'Boehringer Ingelheim (Germany) ', 'MilliporeSigma (United States) ', 'Aenova Group (Germany) ', 'Fareva (France) ', 'Laurus Labs (India) ', 'Delpharm (France) ', 'Piramal Pharma Solutions (India) ', 'Almac Group (United Kingdom) ', 'Evonik Industries (Germany) ', 'Cambrex Corporation (United States) ', 'Lonza Group (Switzerland) ', 'Patheon (United States) ', 'WuXi AppTec (China) '

Owing to expanding acceptance of a westernized lifestyle, rising economic development, and rising population, the burden of chronic illnesses is rising significantly over the world. About 133 million Americans suffer from chronic illnesses, accounting for more than 40% of the nation's population and being typically incurable and continuous. It is anticipated that by 2020, there would be 157 million people worldwide, 81 million of whom will have various illnesses. Around 8% of children aged 5 to 17 reported having limited activities because of at least one chronic illness or impairment, while around 50% of adults report having a chronic condition.

Currently, the contract development and manufacturing organization outsourcing market is fragmented. The necessity for quick innovations to provide efficient process solutions to improve the drug development process has increased among pharmaceutical businesses. Many contract development and manufacturing businesses are preferring to combine with small and major pharma & biotech enterprises, along with many life-science corporations, in order to improve their service offerings.

The market in North America is distinguished by the region's long-standing CDMO presence. Along with this element, expanding partnerships between pharmaceutical firms and CDMOs providing a wide variety of services are to blame for the region's leading market share globally. The pharmaceutical business is supported by an estimated 300 pharmaceutical contract development and manufacturing companies (CDMOs). The industry is still incredibly fragmented despite rising merger and acquisition (M&A) activity; the top five CDMOs account for only 15% of the market as a whole.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market
Contract Development And Manufacturing Organization (CDMO) Outsourcing Market

Report ID: SQSG35J2008

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE